Home Contact Sitemap login Checkout

BioAlberta
  • Home
  • About
    • About
    • The BioAlberta Team
    • From The President
    • What We Do
    • Board of Directors
    • Committees
    • Industry Partners
    • Hall Of Fame
  • Boosting Biotech
  • Industry Facts
    • Industry Facts
    • Medical Technology & Devices
    • Health Biotechnology & Pharmaceuticals
    • Agricultural Biotechnology
    • Industrial Biotechnology
    • Functional Foods & Natural Health Products
    • Environmental Biotechnology
    • Industry Terms
  • Events
    • Events
    • Annual Events & Activities
    • Archived Events
      • Archived Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
      • 2017 Events
      • 2016 Events
      • 2015 Events
      • 2014 Events
  • News
    • News
    • Archived News
      • Archived News
      • 2020 News
      • 2019 News
      • 2018 News
      • 2017 news
      • 2016 News
      • 2015 News
      • 2014 News
  • Member Area
    • Member Area
    • Member Marketplace
    • Join Now
    • Member Benefits
      • Member Benefits
      • How To Access Member Benefits
    • Current Members and Life Sciences Industry
    • Current Members by Category
    • Profiled Company
      • Profiled Company
      • Previously Profiled Companies
  • Resources
    • Resources
    • Other Resources
  • Contact
Home Print This Page

ALBERTA-WIDE Funding Opportunity

 
The Alberta Diabetes Institute at the University of Alberta is pleased to announce a collaboration with Janssen Pharmaceuticals and its parent company Johnson & Johnson to advance early-stage technologies related to Type I and Type II diabetes. The Alberta Diabetes Institute - Johnson & Johnson Diabetes Research Fund is a $600,000 partnership between Alberta Diabetes Foundation, Janssen Inc. (Johnson & Johnson) and the Government of Alberta.  The three year competitive fund, administered by U of A’s Alberta Diabetes Institute, will support research in either Type I or Type II diabetes with a focus on highly novel hypothesis-testing for targets, agents, therapies, diagnostics, etc., discovery research with a high potential for commercialization.
 
This is the third year of funding and this year's Letter of Intent is due Monday, March 6, 2017.  LOIs will be evaluated by a review committee that includes industry representation. This will be followed by invitation for full application. Up to a maximum of $50,000 for one year may be requested.
 
Visit Alberta Diabetes Institute for more information.
 
Timelines

  • Letter of Intent due March 6, 2017
  • Notification of approval to submit full application March 20, 2017
  • Full application due April 17, 2017
  • Notification of funding May 23, 2017

 
Additional Reading

  • 2017 Call for LOIs
  • News Release 2016 Awardees
Contact Us
Suite 202
10055 - 106 Street NW
Edmonton, Alberta T5J 2Y2
Canada
Ph:  780.425.3804
Fx:  780.409.9263
admin@BioAlberta.com
Quick Links
Home
About
Industry Facts
News
Events
Member Area
Publications
Contact
Return Policy
Privacy
Terms of Use
Connect
BioAlberta: Twitter linkBioAlberta: linkedin linkBioAlberta: YouTube linkBioAlberta: facebook link